ArticleThe Journal of craniofacial surgery2026
Anticancer Effects of Galium aparine L Extract: Dose-Dependent Cytotoxicity in HNO210 Human Laryngeal Carcinoma Cells.
Article in The Journal of craniofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to examine the cytotoxic effects of extracts from Galium aparine L. on HNO210 human laryngeal cancer cells regarding dosage.
methodsCells from the HNO210 human laryngeal cancer line (BHC11100312; BioHippo) were grown in a specific medium containing fetal bovine serum (10%, 30-2020; ATCC) and antibiotic-antimycotic solution (1%, 15240062; Gibco). The cells were cryopreserved for future use. By diluting the stock in complete medium, 7 working concentrations of Galium aparine L. were prepared: 10, 50, 100, 150, 200, 250, and 500 μL/mL. The colorimetric MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] was used to assess the antiproliferative effects.
resultsHNO210 cells' viability is inhibited by Galium aparine L. Cell metabolic activity was significantly reduced at higher doses, as demonstrated by the concentration-dependent inhibitory effect on viability. The vitality of HNO210 laryngeal carcinoma cells was diminished in a dose-dependent manner following the treatment with Galium aparine L. At higher doses, Galium aparine L. exhibits cytotoxic effects and may hinder the proliferation of cells responsible for the laryngeal cancer. The observed symptoms of cytotoxic stress in cells treated with the extract included reduced cell density, loss of adhesion, and pronounced structural distortion.
conclusionHNO210 laryngeal cancer cells' viability is reduced by the Galium aparine L. Its anticancer effects and cytotoxicity are concentration-dependent. Consistent with its inhibitory impact on cell viability, Galium aparine L. causes significant morphologic deterioration. The antiproliferative properties of Galium aparine L. make it a promising candidate for developing highly effective anticancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.